Neuromuscular Disease News

DENVER — A combination therapeutic for amyotrophic lateral sclerosis was nonsuperior to placebo over 48 weeks in a phase 3 clinical trial, according to a presenter at the American Academy of Neurology annual meeting.

DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole.

The FDA has cleared an investigational new drug application for a small molecule therapeutic to treat those with Fragile X syndrome, according to the manufacturer.

DENVER — Treatment with IV efgartigimod improved functionality for individuals with acetylcholine receptor-positive generalized myasthenia gravis, according to a poster from the American Academy of Neurology annual meeting.

Amylyx Pharmaceuticals Inc. announced Relyvrio, its amyotrophic lateral sclerosis therapeutic, will be removed from the market in the United States and Canada, effective immediately.

A Cincinnati-based life sciences company announced that one of its development candidates, ASHA-624, will be advanced as a potential disease modifying therapy for amyotrophic lateral sclerosis.

March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.

A Boston-area developer of brain-computer interface technology and a Canadian biotech firm have announced a collaboration to globally commercialize the former’s brain health tools.

The FDA has approved Duvyzat for the treatment of Duchenne muscular dystrophy among patients aged 6 years and older, according to a press release.

The FDA has approved breakthrough device designation for a novel neuroimmune modulation platform for those with relapsing-remitting multiple sclerosis, according to the manufacturer.